1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
iSpecimen received a Nasdaq letter dated September 8, 2026, granting an extension until November 25, 2026 to regain compliance with the minimum stockholders' equity requirement. The company says it plans a best-efforts public offering of approximately $5 million in gross proceeds, but the filing states there is no assurance it will regain or maintain compliance, and shareholders could face delisting if it fails to do so.
Nasdaq first notified the company of noncompliance on May 29, 2026, under Listing Rule 5550(b), which requires at least $2,500,000 in stockholders' equity.
The company cites a private placement that closed May 11, 2026, with gross proceeds of approximately $2.5 million, and a planned public offering of approximately $5 million.
Projections show stockholders' equity of approximately $5.1 million through June 30, 2027, per the filing.
The Deficiency Letter has no immediate effect on trading of the common stock on the Nasdaq Capital Market.
GGeoVax Labs said it has requested a Nasdaq Hearings Panel appeal of a delisting determination it received on August 27, 2026, over the minimum bid price requirement, with a hearing scheduled for October 13, 2026. The company says its stock should keep trading on the Nasdaq Capital Market under GOVX at least through that period, and it reaffirmed its focus on the GEO-MVA vaccine program and Gedeptin.
Nasdaq delisting determination received August 27, 2026, relating to the minimum bid price requirement under Listing Rule 5550(a)(2)
Hearing before the Nasdaq Hearings Panel scheduled for October 13, 2026
Hearing request has stayed any suspension or delisting action; GOVX expected to keep trading at least through that period
GeoVax plans to present a compliance plan to regain and maintain listing standards
Nasdaq notified Global Interactive Technologies (GITS) on September 10, 2026 that the company is back in compliance with a listing rule after it filed its overdue quarterly report on Form 10-Q for the period ended June 30, 2026. The company had received a notice on August 20, 2026 that it had missed the filing deadline, which could have led to delisting from Nasdaq if not resolved.
Nasdaq notice dated August 20, 2026 cited late filing of the Form 10-Q under Listing Rule 5250(c)(1)
Form 10-Q for the period ended June 30, 2026 was filed on September 9, 2026
Nasdaq confirmed compliance in a notice received September 10, 2026
20/20 Biolabs, Inc. (AIDX) received a Nasdaq notice on September 3, 2026 saying it does not meet the $2,500,000 stockholders' equity requirement, based on its Form 10-Q showing $1,620,700 at June 30, 2026. The company has 45 calendar days to submit a compliance plan, and failing to regain compliance could bar it from the extra time it would otherwise get on the bid price issue, adding delisting risk for shareholders.
September 3, 2026: Nasdaq notice citing stockholders' equity of $1,620,700 versus a $2,500,000 requirement
Company has 45 calendar days to submit a plan to regain compliance; Nasdaq may grant up to 180 more days if accepted
Separate July 17, 2026 notice on the $1.00 bid price rule; compliance deadline is January 13, 2027
Missing the equity rule by January 13, 2027 would disqualify the company from a second bid price compliance period
On September 9, 2026, DuPont, Chemours and Corteva entered a settlement with the State of North Carolina and 11 local entities to resolve PFAS-related claims, including claims tied to the Fayetteville Works facility and AFFF-related contamination. The settlement is subject to entry of orders dismissing the covered claims, and DuPont recorded a probable loss of about $125 million in the second quarter of 2026, which the press release says is materially covered by existing accruals.
Aggregate cash payment of $455 million to the plaintiffs, payable over 15 years, shared under the 2021 MOU; $18 million is attributed to PFAS contamination unrelated to Fayetteville Works.
DuPont recorded a probable loss of about $125 million in Q2 2026 within discontinued operations, before Qnity Electronics' reimbursement of 44% of DuPont's share.
DuPont and Corteva will establish a $135 million Reserve Fund, accessible only if Chemours fails to perform under its 2019 Consent Order with the State.
Future MOU escrow contributions, including the one due in September 2026, will be considered satisfied by the New Jersey and North Carolina settlement payments.
Chemours, DuPont and Corteva agreed on September 9, 2026 to settle PFAS-related claims by the State of North Carolina and 11 local entities, including claims tied to the Fayetteville Works facility. Chemours will pay 50% of the $455 million settlement under the 2021 cost-sharing memorandum, and the company says its share is covered by existing accruals. The settlement remains subject to court orders dismissing the covered claims.
Total settlement payments are $455 million over 15 years, beginning within 30 days of the agreement's execution date.
Chemours' 50% share is approximately $180 million on a net present value basis, which the company says is covered by existing accruals.
Chemours expects to pay approximately $50 million over the next twelve months.
All future MOU escrow contributions are considered satisfied, including Chemours' $50 million contribution that would have been due in September 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.